Get the Stockscreener App
0.5889
41.03%
-0.5811
After Hours:
.59
0.00107
+0.18%
Brainstorm Cell Therapeutics Inc stock is traded at $0.5889, with a volume of 38,613.
It is down -41.03% in the last 24 hours and down -43.90% over the past month.
BRAINSTORM CELL THERAPUTC
See More
Previous Close:
$1.17
Open:
$0.6
24h Volume:
38,613
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-16.63M
P/E Ratio:
-1.3696
EPS:
-0.43
Net Cash Flow:
$-21.84M
1W Performance:
-41.03%
1M Performance:
-43.90%
6M Performance:
-68.49%
1Y Performance:
-87.10%
1-Day Range:
$0.555
$0.6166
1-Week Range:
$0.555
$0.6166
52-Week Range:
$0.555
$0.6166
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Name
Brainstorm Cell Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare BCLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
0.5889 | 0 | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-21 | Upgrade | Maxim Group | Hold → Buy |
| Nov-17-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-19-16 | Reiterated | Maxim Group | Buy |
| Dec-22-15 | Reiterated | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Latest News
Is Brainstorm Cell Therapeutics Inc GHD a good long term investmentIPO Market Watch & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Can Brainstorm Cell Therapeutics Inc. stock outperform in 2025 bull marketMarket Risk Report & Free Daily Entry Point Trade Alerts - Улправда
Why Brainstorm Cell Therapeutics Inc. stock appeals to analysts2025 Winners & Losers & Daily Stock Trend Watchlist - Улправда
Why Brainstorm Cell Therapeutics Inc. stock remains a top recommendationDip Buying & Capital Efficiency Focused Strategies - DonanımHaber
Is Brainstorm Cell Therapeutics Inc. stock dividend yield sustainableJuly 2025 Decliners & Target Return Focused Stock Picks - DonanımHaber
Can Brainstorm Cell Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Reactions & Weekly Top Stock Performers List - DonanımHaber
How Brainstorm Cell Therapeutics Inc. stock reacts to global recession fearsJuly 2025 Sentiment & Proven Capital Preservation Methods - DonanımHaber
Will Brainstorm Cell Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Institutional & Real-Time Volume Triggers - Улправда
Maxim Group downgrades Brainstorm Cell Therapeutics (BCLI) - MSN
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy - Cantech Letter
BrainStorm Cell Therapeutics Reports Q3 2025 Financials and Updates - MSN
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
Why analysts raise outlook for Brainstorm Cell Therapeutics Inc. (GHD) stockTrade Exit Summary & Low Risk High Win Rate Picks - Newser
Can Brainstorm Cell Therapeutics Inc. (GHD) stock sustain double digit ROEWeekly Trend Report & Fast Gain Stock Tips - Newser
Will Brainstorm Cell Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Sentiment & Safe Entry Point Alerts - Newser
How Brainstorm Cell Therapeutics Inc. (GHD) stock trades in high volatilityWeekly Investment Recap & Community Supported Trade Ideas - Newser
Why analysts recommend Brainstorm Cell Therapeutics Inc. (GHD) stockWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
How supply chain issues affect Brainstorm Cell Therapeutics Inc. stock2025 Macro Impact & Free Accurate Trade Setup Notifications - Newser
What hedge fund moves indicate for Brainstorm Cell Therapeutics Inc. (GHD) stockPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
How Brainstorm Cell Therapeutics Inc. (GHD) stock valuation compares with sector2025 EndofYear Setup & Trade Opportunity Analysis Reports - Newser
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Aktiellt
BCLI Interactive Stock Chart | BrainStorm Cell Therapeutics In Stock - Yahoo Finance
FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness (PR Newswire) - Aktiellt
Will Brainstorm Cell Therapeutics Inc. (GHD) stock outperform energy sector in 2025Weekly Profit Report & Accurate Buy Signal Notifications - newser.com
How higher bond yields impact Brainstorm Cell Therapeutics Inc. (GHD) stockTrade Entry Summary & Safe Entry Point Identification - newser.com
Will Brainstorm Cell Therapeutics Inc. (GHD) stock see valuation expansion2025 Trading Recap & Growth Oriented Trade Recommendations - newser.com
Can Brainstorm Cell Therapeutics Inc. stock hit record highs againWeekly Market Summary & Real-Time Market Sentiment Reports - newser.com
Why Brainstorm Cell Therapeutics Inc. stock remains on watchlistsJuly 2025 Sector Moves & Stepwise Trade Execution Plans - newser.com
Long term hold vs stop loss in Brainstorm Cell Therapeutics Inc.Quarterly Profit Report & AI Driven Price Forecasts - newser.com
Real time social sentiment graph for Brainstorm Cell Therapeutics Inc.2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
What momentum indicators show for Brainstorm Cell Therapeutics Inc. stockNew Guidance & Daily Price Action Insights - newser.com
Can a trend reversal in Brainstorm Cell Therapeutics Inc. lead to recoveryGlobal Markets & Weekly Stock Breakout Alerts - newser.com
Brainstorm Cell Therapeutics Inc Stock (BCLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Cap:
|
Volume (24h):